Boehringer, Zealand Begin Phase III Program For Obesity Contender Survodutide

Studies Include Cardiovascular Outcomes Trial

 
• By Mandy Jackson

The partners revealed Phase III trial details for GLP-1/glucagon agonist survodutide, where the biggest challenge may be overcoming gastrointestinal side effects seen in Phase II.

Nutritionist sitting at her desk
The three-trial Phase III program will begin enrolling patients soon • Source: Shutterstock

More from Clinical Trials

More from R&D